Xybion Logo

Investor Relations

Xybion is poised for rapid growth in a growing market. Contact us today for investor inquiries.

Xybion Accelerates the Digital Transformation of Pharmaceutical and Life Science Industries

With Innovative Software Used by the Most Reputable Brands in the World

Delivering Value

Xybion provides digital frameworks for highly regulated business processes primarily in the health sciences market. Its software is deployed at the FDA and also several major drug developers & producers. Xybion’s software replaced legacy paper-based approval processes with integrated digital systems for trial enrollment, results and approvals with the FDA at Pfizer, Moderna, J&J for the COVID-19 vaccines, and for Merck’s antiviral medicine. As a result, Xybion was one of the underlying digital systems that helped to accelerate the development and approval of the life-saving COVID-19 vaccines globally.

The Growing Market

Building upon this success in life sciences, Xybion is poised to expand dramatically over the next several years by becoming a proven digital transformation engine for highly regulated business processes. Building upon its base of approximately C$23M of annual revenue, contracted revenue, backlog, and the current sales pipeline combine to imply organic growth potential for the next few years of between 20% and 25% per annum. The company is already profitable and cash-flow positive, and is intent on trading on a public exchange to:

1.         Attract highly skilled labor with share option plans that retain future liquidity.

 

2.       Assemble adequate capital to acquire scale, complimentary solutions, and protected market share at a faster pace than as a private company.

Strategic, Diversified Growth Portfolio

Management already has a list of potential targets, and a history of acquiring and integrating companies. Xybion itself is an amalgamation of three companies. Approximately 60% of its total annual revenue is SaaS-based and recurring, up from zero percent three years ago. Most of Xybion’s organic revenue growth will continue to be driven by recurring revenue for the foreseeable future.

XYBN Portfolio.

HEADQUARTERS

105 College Road East
Princeton, New Jersey 08540

© Copyright 2022 Xybion Digital Inc.
All Rights Reserved.

Contact Investor Relations

Unified All-In-One Cloud Software Solutions for Life Sciences, Health Systems, and Regulated Industries.

Contact Investor Relations

Unified All-In-One Cloud Software Solutions for Life Sciences, Health Systems, and Regulated Industries.

Xybion Logo White

HEADQUARTERS

105 College Road East
Princeton, New Jersey 08540

INVESTOR RELATIONS

© Copyright 2022 Xybion Digital Inc. All Rights Reserved.

Contact Investor Relations

Unified All-In-One Cloud Software Solutions for Life Sciences, Health Systems, and Regulated Industries.

Xybion Logo White

INVESTOR RELATIONS

HEADQUARTERS

105 College Road East
Princeton, New Jersey 08540

© Copyright 2022 Xybion Digital Inc.
All Rights Reserved.

© Copyright 2021 Xybion Corporation. All Rights Reserved.